Market Cap (In USD)
8.1 Billion
Revenue (In USD)
266.71 Million
Net Income (In USD)
-481.44 Million
Avg. Volume
577.06 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 111.09-161.0
- PE
- -
- EPS
- -
- Beta Value
- 0.654
- ISIN
- US04351P1012
- CUSIP
- 04351P101
- CIK
- 1612042
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jan Moller Mikkelsen
- Employee Count
- -
- Website
- https://ascendispharma.com
- Ipo Date
- 2015-01-28
- Details
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
More Stocks
-
0859
-
LLFICL
-
ADVM
-
AFMDAffimed N.V.
AFMD
-
GLITTEKGGlittek Granites Limited
GLITTEKG
-
IFCIIFCI Limited
IFCI
-
BESTAGROBest Agrolife Limited
BESTAGRO
-
INCREDIBLEIncredible Industries Limited
INCREDIBLE